Abstract
A 36-year-old woman was referred to our department for the recent onset lower limbs edema, high-grade proteinuria, and microscopic hematuria. The patient had a history of a relapsing-remitting multiple sclerosis in 2010, initially treated by interferon, which was replaced by fingolimod in 2012 given persistent disease activity. In 2016, after 2 severe flares with only partial recovery, fingolimod was switched to alemtuzumab. Accordingly, the patient was monitored regularly for potential adverse events, including monthly measurement of serum creatinine level and urinalysis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
